Great Lakes Advisors LLC Has $1.67 Million Stock Position in Lantheus Holdings, Inc. $LNTH

Great Lakes Advisors LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 23.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,535 shares of the medical equipment provider’s stock after selling 9,934 shares during the period. Great Lakes Advisors LLC’s holdings in Lantheus were worth $1,669,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Stanley Laman Group Ltd. increased its stake in shares of Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after acquiring an additional 22,229 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Lantheus during the third quarter valued at approximately $2,184,000. Y Intercept Hong Kong Ltd bought a new stake in Lantheus in the third quarter valued at approximately $3,866,000. Fox Run Management L.L.C. acquired a new stake in Lantheus in the second quarter worth $654,000. Finally, Nordea Investment Management AB boosted its position in shares of Lantheus by 1.6% during the second quarter. Nordea Investment Management AB now owns 48,075 shares of the medical equipment provider’s stock worth $3,913,000 after purchasing an additional 737 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on LNTH. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Mizuho raised their price target on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Truist Financial lifted their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Stock Performance

LNTH opened at $66.92 on Friday. The company has a market capitalization of $4.44 billion, a price-to-earnings ratio of 28.12 and a beta of -0.11. The business’s 50-day moving average price is $64.87 and its two-hundred day moving average price is $59.88. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $384.01 million during the quarter, compared to the consensus estimate of $363.42 million. During the same period last year, the company earned $1.70 earnings per share. Lantheus’s quarterly revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.